NCT03517813
Completed
Not Applicable
Comparative Performance of Contrast-enhanced Spectral Mammography (CESM) and Abbreviated Breast MRI (ABMR) With Standard Breast MRI for Breast Cancer Screening
ConditionsBreast Cancer Screening
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Breast Cancer Screening
- Sponsor
- University of Washington
- Enrollment
- 256
- Locations
- 1
- Primary Endpoint
- Abnormal interpretation rate
- Status
- Completed
- Last Updated
- 3 years ago
Overview
Brief Summary
This is a single institution, prospective screening trial of women at high risk for developing breast cancer, enriched with women with suspicious lesions on breast MRI which have been recommended for biopsy.
Primary Aim: Measure and compare the diagnostic performance of CESM, ABMR, and standard breast MRI, using the following performance measures: cancer detection rate (CDR), biopsy rate, and cancer yield of biopsy (also known as positive predictive value 3 or PPV3).
Secondary Aims:
- Compare screening performance outcome measures of sensitivity, specificity, and area under the receiver operating characteristic curve (AUC) for CESM, ABMR, and standard breast MRI. This will determine the feasibility of each modality as an alternative to standard breast MRI and provide valuable pilot data for designing a larger clinical trial to evaluate non-inferiority of either or both modalities.
- Breast cancer characteristics (size, histologic subtype, node-positivity, AJCC stage) will be assessed in the overall cohort, and stratified by mode of detection for each modality(screen-detected versus interval).
Investigators
Eligibility Criteria
Inclusion Criteria
- •Able and willing to provide signed declaration of informed consent or have a legally authorized representative provide signed declaration of informed consent for participation in all study procedures;
- •Women aged ≥18 years at the time of enrollment
- •Referred clinically for breast MRI for any indication
Exclusion Criteria
- •Known allergy or contraindication to iodinated contrast
- •Are currently pregnant based on urine pregnancy test
- •Have breast implants
- •Are lactating
Outcomes
Primary Outcomes
Abnormal interpretation rate
Time Frame: 2 years
Abnormal interpretation rates for each modality (CESM, abbreviated breast MRI, standard breast MRI)
Secondary Outcomes
- Negative predictive value(3 years)
- Cancer detection rate(3 years)
- Biopsy rate(2 years)
- Sensitivity(2 years)
- Positive predictive value for biopsy recommendation (PPV2)(3 years)
- Specificity(2 years)
Study Sites (1)
Loading locations...
Similar Trials
Unknown
Not Applicable
Evaluate the Safety and Effectiveness of Using Echogenic Embolic Agent for Embolization of Prostate Artery for Treatment of Men With BPH (PAE CEUS)Benign Prostatic HyperplasiaNCT04267445University of Calgary15
Active, not recruiting
Not Applicable
Tomosynthesis vs. Contrast-Enhanced Mammography in Women With Personal History of Breast Cancer in Western PennsylvaniaBreast Cancer FemaleBreast CancerBreast NeoplasmsNeoplasmsNCT04085510Wendie Berg1,647
Recruiting
Not Applicable
Biennial CEM in Women With a Personal History of Breast CancerBreast CancerBreast NeoplasmsBreast Cancer FemaleNeoplasmsNCT06105749Wendie Berg1,500
Recruiting
Not Applicable
An Imaging Technology, Contrast-Enhanced Mammography, in Predicting Breast CancerBreast CarcinomaNCT04871139M.D. Anderson Cancer Center100
Recruiting
Not Applicable
Contrast Enhanced Spectral Mammography for the Evaluation of Pathologic Nipple DischargeBreast CarcinomaNCT05056844M.D. Anderson Cancer Center66